{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:36Z","timestamp":1744258896455,"version":"3.40.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01162-7","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T03:23:23Z","timestamp":1744082603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engagement in hepatitis C virus cascade of care and factors associated with testing among people who inject drugs in Iran"],"prefix":"10.1186","volume":"22","author":[{"given":"Mehrdad","family":"Khezri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Mehmandoost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidar","family":"Sharafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maliheh Sadat","family":"Bazrafshani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Moameri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Akbar","family":"Haghdoost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Des Jarlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drugpo.2019.07.002","volume":"72","author":"M Alavi","year":"2019","unstructured":"Alavi M, Poustchi H, Merat S, Kaveh-Ei S, Rahimi-Movaghar A, Shadloo B, Hajarizadeh B, Grebely J, Dore GJ, Malekzadeh R. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: the ENHANCE study. Int J Drug Policy. 2019;72:99\u2013105.","journal-title":"Int J Drug Policy"},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-019-0842-5","volume":"19","author":"L Avery","year":"2019","unstructured":"Avery L, Rotondi N, McKnight C, Firestone M, Smylie J, Rotondi M. Unweighted regression models perform better than weighted regression techniques for respondent-driven sampling data: results from a simulation study. BMC Med Res Methodol. 2019;19:1\u201313.","journal-title":"BMC Med Res Methodol"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","volume":"47","author":"S Bajis","year":"2017","unstructured":"Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34\u201346.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1162_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jvh.13233","volume":"27","author":"S Bajis","year":"2020","unstructured":"Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, Byrne J, Bath N, Read P, Edwards M. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: the LiveRLife study. J Viral Hepatitis. 2020;27(3):281\u201393.","journal-title":"J Viral Hepatitis"},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"102755","DOI":"10.1016\/j.drugpo.2020.102755","volume":"80","author":"J Broad","year":"2020","unstructured":"Broad J, Mason K, Guyton M, Lettner B, Matelski J, Powis J. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto. Canada Int J Drug Policy. 2020;80:102755.","journal-title":"Canada Int J Drug Policy"},{"issue":"3","key":"1162_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hep4.1310","volume":"3","author":"H Chemaitelly","year":"2019","unstructured":"Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to test for hepatitis C virus in the Middle East and North Africa? Pooled analyses of 2500 prevalence measures, including 49 million tests. Hepatol Commun. 2019;3(3):325\u201339.","journal-title":"Hepatol Commun"},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","volume":"111","author":"EB Cunningham","year":"2023","unstructured":"Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Bajis S, Valencia BM. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis. Int J Drug Policy. 2023;111:103917.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1162_CR8","first-page":"269","volume":"32","author":"GJ Dore","year":"2018","unstructured":"Dore GJ, Hajarizadeh B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect Dis Clin. 2018;32(2):269\u201379.","journal-title":"Infect Dis Clin"},{"issue":"7","key":"1162_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/add.14905","volume":"115","author":"H Ekhtiari","year":"2020","unstructured":"Ekhtiari H, Noroozi A, Farhoudian A, Radfar SR, Hajebi A, Sefatian S, Zare-bidoky M, Razaghi EM, Mokri A, Rahimi-Movaghar A. The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity? Addiction. 2020;115(7):1395\u2013403.","journal-title":"Addiction"},{"issue":"8","key":"1162_CR10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/add.14608","volume":"114","author":"L Elliott","year":"2019","unstructured":"Elliott L, Bennett AS, Wolfson-Stofko B. Life after opioid-involved overdose: survivor narratives and their implications for ER\/ED interventions. Addiction. 2019;114(8):1379\u201386.","journal-title":"Addiction"},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"102981","DOI":"10.1016\/j.drugpo.2020.102981","volume":"87","author":"J Friedman","year":"2021","unstructured":"Friedman J, Syvertsen JL, Bourgois P, Bui A, Beletsky L, Pollini R. Intersectional structural vulnerability to abusive policing among people who inject drugs: a mixed methods assessment in California\u2019s central Valley. Int J Drug Policy. 2021;87:102981.","journal-title":"Int J Drug Policy"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"109050","DOI":"10.1016\/j.drugalcdep.2021.109050","volume":"228","author":"D Gibbs","year":"2021","unstructured":"Gibbs D, Price O, Grebely J, Larney S, Sutherland R, Read P, Butler K, Degenhardt L, Peacock A. Hepatitis C virus cascade of care among people who inject drugs in Australia: factors associated with testing and treatment in a universal healthcare system. Drug Alcohol Depend. 2021;228:109050.","journal-title":"Drug Alcohol Depend"},{"key":"1162_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104324","author":"HD Gliddon","year":"2024","unstructured":"Gliddon HD, Ward Z, Heinsbroek E, Croxford S, Edmundson C, Hope V, Simmons R, Mitchell H, Hickman M, Vickerman P. Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals? Int J Drug Policy. 2024. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104324.","journal-title":"Int J Drug Policy"},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugpo.2019.02.012","volume":"72","author":"BL Harney","year":"2019","unstructured":"Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, Pemberton D, Hellard ME, Doyle JS. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int J Drug Policy. 2019;72:195\u20138.","journal-title":"Int J Drug Policy"},{"unstructured":"Hosseini-Hooshyar S, Khezri M, Karamouzian M, Mirzazadeh A, Sharifi H, Tavakoli F, Ghalekhani N, Mehmandoost S, Mousavian G, Akbarpour S, Afsar-Kazerooni P, Haghdoost AA, Shokoohi M (2021) Drug use patterns, injection risk behaviours and harm reduction service utilization among people who inject drugs in Iran: results from three consecutive bio-behavioural surveillance surveys. The 2021 International Network on Hepatitis in Substance Users (INHSU) Conference., https:\/\/inhsu.org\/resource\/vp14-drug-use-patterns-injection-risk-behaviours-and-harm-reduction-service-utilization-among-people-who-inject-drugs-in-iran-results-from-three-consecutive-bio-behavioural-surveillance-surveys\/","key":"1162_CR15"},{"key":"1162_CR16","doi-asserted-by":"publisher","first-page":"109751","DOI":"10.1016\/j.drugalcdep.2022.109751","volume":"243","author":"M Khezri","year":"2023","unstructured":"Khezri M, Mirzazadeh A, Shokoohi M, Sharafi H, Ghalekhani N, Tavakoli F, Mehmandoost S, Mousavian G, Imani M, Kakavand-Ghalehnoei R. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran. Drug Alcohol Depend. 2023;243:109751.","journal-title":"Drug Alcohol Depend"},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10461-022-03627-3","volume":"26","author":"M Khezri","year":"2022","unstructured":"Khezri M, Shokoohi M, Mirzazadeh A, Tavakoli F, Ghalekhani N, Mousavian G, Mehmandoost S, Kazerooni PA, Haghdoost AA, Karamouzian M. HIV prevalence and related behaviors among people who inject drugs in Iran from 2010 to 2020. AIDS Behav. 2022;26:1\u201313.","journal-title":"AIDS Behav"},{"issue":"7","key":"1162_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/add.14944","volume":"115","author":"S Mahmud","year":"2020","unstructured":"Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction. 2020;115(7):1244\u201362.","journal-title":"Addiction"},{"issue":"4","key":"1162_CR19","doi-asserted-by":"publisher","first-page":"e0249585","DOI":"10.1371\/journal.pone.0249585","volume":"16","author":"A Mirzazadeh","year":"2021","unstructured":"Mirzazadeh A, Chen Y-H, Lin J, Burk K, Wilson EC, Miller D, Veloso D, McFarland W, Morris MD. Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco. PLoS ONE. 2021;16(4):e0249585.","journal-title":"PLoS ONE"},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"103580","DOI":"10.1016\/j.drugpo.2022.103580","volume":"102","author":"A Mirzazadeh","year":"2022","unstructured":"Mirzazadeh A, Hosseini-Hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: the Rostam study. Int J Drug Policy. 2022;102:103580.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1162_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/add.14853","volume":"115","author":"Y Rahimi","year":"2020","unstructured":"Rahimi Y, Gholami J, Amin-Esmaeili M, Fotouhi A, Rafiemanesh H, Shadloo B, Rahimi-Movaghar A. HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. Addiction. 2020;115(4):605\u201322.","journal-title":"Addiction"},{"key":"1162_CR22","first-page":"6578","volume":"12","author":"A Rastegari","year":"2023","unstructured":"Rastegari A, Baneshi MR, Hajebi A, Noroozi A, Karamouzian M, Shokoohi M, Mirzazadeh A, Bojnourdi TK, Nasiri N, Maghsoudi SH. Population size estimation of people who use illicit drugs and alcohol in Iran (2015\u20132016). Int J Health Policy Manag. 2023;12:6578.","journal-title":"Int J Health Policy Manag"},{"issue":"11","key":"1162_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/jvh.13175","volume":"26","author":"P Read","year":"2019","unstructured":"Read P, Gilliver R, Kearley J, Lothian R, Cunningham EB, Chronister KJ, Dore GJ. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection. J Viral Hepat. 2019;26(11):1301\u201310.","journal-title":"J Viral Hepat"},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/j.drugalcdep.2020.108419","volume":"218","author":"HT Saleem","year":"2021","unstructured":"Saleem HT, Likindikoki S, Nonyane BA, Nkya IH, Zhang L, Mbwambo J, Latkin C. Correlates of non-fatal, opioid overdose among women who use opioids in Dar es Salaam. Tanzan Drug Alcohol Depend. 2021;218:108419.","journal-title":"Tanzan Drug Alcohol Depend"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2019.05.023","volume":"72","author":"ME Soc\u00edas","year":"2019","unstructured":"Soc\u00edas ME, Karamouzian M, Parent S, Barletta J, Bird K, Ti L. Integrated models of care for people who inject drugs and live with hepatitis C virus: a systematic review. Int J Drug Policy. 2019;72:146\u201359.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1162_CR26","doi-asserted-by":"publisher","first-page":"e1002460","DOI":"10.1371\/journal.pmed.1002460","volume":"14","author":"SS Solomon","year":"2017","unstructured":"Solomon SS, McFall AM, Lucas GM, Srikrishnan AK, Kumar MS, Anand S, Quinn TC, Celentano DD, Mehta SH. Respondent-driven sampling for identification of HIV-and HCV-infected people who inject drugs and men who have sex with men in India: a cross-sectional, community-based analysis. PLoS Med. 2017;14(11):e1002460.","journal-title":"PLoS Med"},{"issue":"8","key":"1162_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jvh.12183","volume":"21","author":"C Treloar","year":"2014","unstructured":"Treloar C, Rance J, Dore G, Grebely J, ES Group. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. J Viral Hepat. 2014;21(8):560\u20137.","journal-title":"J Viral Hepat"},{"key":"1162_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.drugpo.2017.12.014","volume":"52","author":"H Valerio","year":"2018","unstructured":"Valerio H, McAuley A, Innes H, Palmateer N, Goldberg DJ, Munro A, Taylor A, Hutchinson SJ. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. Int J Drug Policy. 2018;52:115\u201322.","journal-title":"Int J Drug Policy"},{"unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. 2016","key":"1162_CR29"},{"unstructured":"World Health Organization. Global hepatitis report 2017. World Health Organization. 2017","key":"1162_CR30"},{"key":"1162_CR31","doi-asserted-by":"publisher","first-page":"103821","DOI":"10.1016\/j.drugpo.2022.103821","volume":"109","author":"J-M Yuan","year":"2022","unstructured":"Yuan J-M, Croxford S, Viviani L, Emanuel E, Phipps E, Desai M. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: a quantitative cross-sectional analysis. Int J Drug Policy. 2022;109:103821.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01162-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:46:23Z","timestamp":1744217183000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01162-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01162-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All study protocols were reviewed and approved by the ethics committee of Kerman University of Medical Sciences (Ethics Codes: IR.KMU.REC.1401.216). Participation in the study was anonymous, and verbal informed consent was obtained from all participants before their enrollment, encompassing both biological and behavioral data collection and declining to participate did not affect service or care provision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have confirmed they have no potential conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}